- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05850689
Étude de Lumateperone en tant que traitement d'appoint dans le traitement de patients atteints de trouble dépressif majeur
Une étude multicentrique randomisée, en double aveugle et contrôlée par placebo pour évaluer l'efficacité et l'innocuité de la lumatepérone en tant que traitement d'appoint dans le traitement des patients atteints de trouble dépressif majeur
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study will be conducted in three periods:
- Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
- Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
- Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Study Contact
- Numéro de téléphone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Lieux d'étude
-
-
-
Cherven Bryag, Bulgarie, 5980
- Recrutement
- Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
-
Kardzhali, Bulgarie, 6600
- Recrutement
- Medical Center Lifemed
-
Pleven, Bulgarie, 5800
- Recrutement
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgarie, 4004
- Recrutement
- Medical Center Mentalcare OOD
-
Sofia, Bulgarie, 1680
- Recrutement
- Medical Center Intermedica, OOD
-
Sofia, Bulgarie, 1510
- Recrutement
- Medical Center Hera EOOD
-
Sofia, Bulgarie, 1202
- Recrutement
- MHC - Sofia, EOOD
-
Sofia, Bulgarie, 1431
- Résilié
- University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
-
Stara Zagora, Bulgarie, 6003
- Complété
- UMHAT Prof. Dr. St. Kirkovich AD
-
Varna, Bulgarie, 9020
- Recrutement
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Barcelona, Espagne, 08036
- Recrutement
- Hosp. Clinic de Barcelona
-
Barcelona, Espagne, 08035
- Recrutement
- Hosp Univ Vall D Hebron
-
Madrid, Espagne, 28034
- Complété
- Hosp. Univ. Ramon Y Cajal
-
Sabadell, Espagne, 08208
- Recrutement
- Hosp.Univ.Parc Tauli
-
Zamora, Espagne, 49021
- Recrutement
- Hosp. Prov. de Zamora
-
-
-
-
-
Douai, France, 59500
- Recrutement
- Cabinet Medical des Drs Prizac-Desbonnet Scottez
-
Nantes, France, 44093
- Recrutement
- CHU de Nantes hotel Dieu
-
Nîmes, France, 30029
- Recrutement
- Hopital Caremeau
-
Paris, France, 75012
- Recrutement
- Groupe Hospitalier Pitie-Salpetriere
-
Poitiers, France, 86021
- Recrutement
- CH Henri Laborit
-
-
-
-
-
Ahmedabad, Inde, 380008
- Suspendu
- Ratandeep Surgical Hospital And Endoscopy Clinic
-
Ahmedabad, Inde, 380009
- Suspendu
- Sushrusha Navneet Memorial Hospital
-
Ajmer, Inde, 305001
- Suspendu
- J L N Medical College and Attached Hospitals
-
Bikaner, Inde, 334001
- Recrutement
- S P Medical College And Associated Group of Hospitals
-
Bārāmati, Inde, 413102
- Recrutement
- Baramati Hospital
-
Chandigarh, Inde, 160012
- Recrutement
- Post Graduate Institute of Medical Education And Research PGIMER
-
Guwahati, Inde, 781032
- Complété
- Gauhati Medical College and Hospital
-
Kolhāpur, Inde, 416001
- Recrutement
- Swastik Hospital
-
Nagpur, Inde, 440001
- Recrutement
- KIMS-Kingsway Hospitals
-
Palsāna, Inde, 394315
- Recrutement
- Divyam Hospital
-
Pune, Inde, 411011
- Recrutement
- Shree Samarth Hospital
-
Rajkot, Inde, 360001
- Complété
- Nagecha Hospital
-
Wardha, Inde, 442004
- Suspendu
- Acharya vinoba bhave rural hospital
-
-
-
-
-
Kaunas, Lituanie, LT-44279
- Complété
- Romuvos Klinika, JSC
-
Ziegzdriai, Lituanie, 53136
- Complété
- Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
-
-
-
-
-
Belgrade, Serbie, 11000
- Recrutement
- University Clinical Center of Serbia
-
Belgrade, Serbie, 11000
- Recrutement
- Institute of Mental Health Serbia
-
Belgrade, Serbie, 11000
- Recrutement
- Clinical Center Dr Dragisa Misovic Dedinje
-
Kovin, Serbie, 26220
- Recrutement
- Special Hospital for Psychiatric Diseases Kovin
-
Kragujevac, Serbie, 34000
- Recrutement
- University Clinical Center Kragujevac
-
Kragujevac, Serbie, 34000
- Recrutement
- University Clinical Center Kragujevac 1
-
Niš, Serbie, 18000
- Recrutement
- University Clinical Center NIS 1
-
Niš, Serbie, 18000
- Recrutement
- University Clinical Center NIS
-
Novi Kneževac, Serbie, 23330
- Recrutement
- Special Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
Alabama
-
Huntsville, Alabama, États-Unis, 35801
- Recrutement
- University of Alabama at Birmingham
-
-
California
-
Pico Rivera, California, États-Unis, 90660
- Recrutement
- CNRI-Los Angeles, LLC
-
-
Connecticut
-
Farmington, Connecticut, États-Unis, 06030
- Recrutement
- University of Connecticut Health Center
-
-
Florida
-
Clermont, Florida, États-Unis, 34711
- Résilié
- Vertex Clinical Research
-
Hialeah, Florida, États-Unis, 33012
- Suspendu
- New Life Medical Research Center, Inc.
-
Miami, Florida, États-Unis, 33122
- Recrutement
- Premier Clinical Research Institute
-
Miami, Florida, États-Unis, 33137
- Recrutement
- Miami Jewish Health System
-
Tampa, Florida, États-Unis, 33629
- Recrutement
- Interventional Psychiatry of Tampa Bay
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- Recrutement
- The Emory Clinic
-
Decatur, Georgia, États-Unis, 30030
- Recrutement
- CenExeli Research LLC
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Résilié
- University of Kansas Medical Center Research Institute
-
Overland Park, Kansas, États-Unis, 66210
- Recrutement
- Collective Medical Research
-
-
Massachusetts
-
Methuen, Massachusetts, États-Unis, 01844
- Résilié
- ActivMed Practices and Research
-
-
Missouri
-
O'Fallon, Missouri, États-Unis, 63368
- Recrutement
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, États-Unis, 08755
- Recrutement
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, États-Unis, 11235
- Recrutement
- SPRI Clinical Trials, LLC
-
New York, New York, États-Unis, 10036
- Recrutement
- Manhattan Behavioral Medicine
-
-
Ohio
-
Avon Lake, Ohio, États-Unis, 44012
- Recrutement
- Quest Therapeutics of Avon Lake
-
Cincinnati, Ohio, États-Unis, 45219
- Recrutement
- University of Cincinnati Medical Center
-
Columbus, Ohio, États-Unis, 43210
- Recrutement
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- University of Pennsylvania - Perelman School of Medicine
-
-
Texas
-
Houston, Texas, États-Unis, 77081
- Recrutement
- DM Clinical Research
-
Mansfield, Texas, États-Unis, 76063
- Complété
- Hawkins Psychiatry, PC
-
Richardson, Texas, États-Unis, 75080
- Recrutement
- Pillar Clinical Research, LLC
-
-
Washington
-
Bellevue, Washington, États-Unis, 98007
- Recrutement
- Northwest Clinical Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Male or female patients between the ages of 18 and 65 years, inclusive;
-
Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:
- The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
- Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
- Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
- Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
- Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-
Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
- citalopram/escitalopram
- fluoxetine
- paroxetine
- sertraline
- duloxetine
- levomilnacipran/milnacipran (if locally approved for MDD)
- venlafaxine/desvenlafaxine
- bupropion
- vilazodone
- vortioxetine
Exclusion Criteria:
-
Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
- Eating disorder;
- Substance use disorders (excluding nicotine);
- Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
- Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
-
The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
-
The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
- At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
- The patient is considered to be in imminent danger to him/herself or others.
-
The patient has a first MDE at age 60 years or older.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
|
Matching capsules administered orally, once daily |
|
Expérimental: Lumatepérone 42 mg
|
Lumateperone 42 mg capsules administered orally, once daily |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale
Délai: Day 43
|
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms. |
Day 43
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Clinical Global Impression Scale-Severity
Délai: Day 43
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Day 43
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ITI-007-505
- ITI-007-505 (Autre identifiant: Janssen Research & Development, LLC)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .